Literature DB >> 2852576

Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast.

V C Jordan1, M F Wolf, D M Mirecki, D A Whitford, W V Welshons.   

Abstract

The revision of the subcellular model of hormone action is described, with an incorporation of potential autocrine mechanisms. A general overview of available assay methodologies considers the major disadvantages of earlier methods and describes in detail the current methodologies (sucrose gradient analysis, dextran-coated charcoal assays, ER-EIA, ERICA). A major concern with clinical correlations of response to hormone receptor levels is the quality assurance of the multicentric programs. Results from national and international programs are considered. The clinical correlations are divided into four major categories: (1) the response to hormone deprivation (oophorectomy or adrenalectomy), (2) the development of specific agents which exploit receptor mechanisms (antiestrogens) or inhibit steroid biosynthesis (aminoglutehimide), (3) the rates of recurrence of tumors following mastectomy, and (4) the correlation of hormone receptors with current adjuvant therapies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2852576     DOI: 10.3109/10408368809106860

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  17 in total

1.  GAS6 is an estrogen-inducible gene in mammary epithelial cells.

Authors:  Rigen Mo; Yiwei Tony Zhu; Zhongyi Zhang; Sambasiva M Rao; Yi-Jun Zhu
Journal:  Biochem Biophys Res Commun       Date:  2006-12-11       Impact factor: 3.575

Review 2.  Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.

Authors:  H M Bryson; G L Plosker
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

3.  The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model.

Authors:  D F Gibson; D A Johnson; S M Langan-Fahey; M K Lababidi; W H Wolberg; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993-09       Impact factor: 4.872

Review 4.  The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.

Authors:  V Craig Jordan
Journal:  Endocr Relat Cancer       Date:  2014-10-22       Impact factor: 5.678

Review 5.  The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.

Authors:  Ping Fan; Philipp Y Maximov; Ramona F Curpan; Balkees Abderrahman; V Craig Jordan
Journal:  Mol Cell Endocrinol       Date:  2015-06-05       Impact factor: 4.102

Review 6.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

7.  Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure.

Authors:  George W Woodfield; Michael J Hitchler; Yizhen Chen; Frederick E Domann; Ronald J Weigel
Journal:  Clin Cancer Res       Date:  2009-05-19       Impact factor: 12.531

Review 8.  William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy.

Authors:  D M Wolf; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 9.  Molecular aspects of estrogen receptor variants in breast cancer.

Authors:  S A Fuqua; D M Wolf
Journal:  Breast Cancer Res Treat       Date:  1995-09       Impact factor: 4.872

10.  Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice.

Authors:  D M Wolf; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.